Logo - International Journal of Pharmaceutical Compounding

Literature Review: The Dual Role of Domperidone in Gastroparesis and Lactation

Author(s):  Phan Ha, DeReese Annie, Day A J, Carvalho Maria

Issue:  May/Jun 2014 - Volume 18, Number 3
View All Articles in Issue

Abstract:  Domperidone is a prokinetic agent used as a second-line treatment option for gastroparesis in those unable to tolerate metoclopramide. Via inhibition of dopamine- 2 receptors within the gastrointestinal tract and various parts of the central and peripheral nervous system, domperidone helps to facilitate peristalsis and gastric emptying. A major side effect of domperidone is prolactinemia, allowing it to be used off-label for the purpose of inducing lactation. In the U.S., domperidone is currently not U.S. Food and Drug Administration approved due to various case reports and literature associating the risks of sudden cardiac death and ventricular arrhythmia with the use of domperidone. Despite the evidence against the use of domperidone, it is still being widely used in Canada and Europe for both gastroparesis and to induce milk let-down. This article is a literature review intending to assess the risks associated with the use of domperidone in gastroparesis and lactation.

Related Keywords: Ha Phan, Annie DeReese, PharmD, RPh, A.J. Day, PharmD, RPh, Maria Calvalho, PharmD, MRPharmS, PhD, domperidone, prokinetic agent, dopamine 2 receptors, prolactinemia, lactation induction, U.S. Food and Drug Administration, FDA, sudden cardiac death, arrhythmia, gastrointestinal motility, prolonged QTc interval, breast milk


Purchase this article for download in electronic PDF format from IJPC at for $35 at:

Search the entire IJPC archive by keyword, topic, or issue at: